For patients with HER2+ breast cancer with a resectable HER2+ local relapse within 12 months of completion of standard adjuvant therapy including 1 year of trastuzumab, what adjuvant therapy would you recommend?
Does hormone receptor status impact your decision?
How would you interpret the results from CALOR tri...
The women who benefited most in the CALOR trial we...